FindTrial
Sign In

A study to evaluate the effects of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.

A study to evaluate the effects of human lymphoblastoid interferon (HLBI) in hepatitis C patients with compensated cirrhosis.

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220477
Enrollment
Unknown
Registered
2007-12-05
Start date
2007-12-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C with compensated cirrhosis

Interventions

investigational material(s) Generic name etc : HLBI (Interferon Alfa (NAMALWA)) INN of investigational material : Therapeutic category code : 625 Anti-virus agents Dosage and Administration for Inves

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Compensated cirrhosis patients -Patients aged 20 to less than 76 etc. -Patients with chronic liver diseases except chronic hepatitis C with compensated cirrhosis, such as autoimmune hepatitis, alcoholic hepatitis, and drug-induced liver injury. -Decompensated cirrhosis patients etc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy: Sustained viral response rates, etc. Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026